5-acetyl-2-phenyl-2,3-dihydropyridazin-3-one | 1258788-62-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-acetyl-2-phenyl-2,3-dihydropyridazin-3-one
• 英文别名: 5-Acetyl-2-phenylpyridazin-3-one
• CAS: 1258788-62-3
• 化学式: C₁₂H₁₀N₂O₂
• 分子量: 214.224
• InChiKey: JXCFZEIVEYDXNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  49.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-acetyl-2-phenyl-2,3-dihydropyridazin-3-one 、 4-氯苯甲醛 在 silica-supported aluminum chloride 作用下， 以 1,4-二氧六环 为溶剂， 以55%的产率得到5-[3-(4-chlorophenyl)prop-2-enoyl]-2-phenylpyridazin-3-one
  参考文献：
  名称：

  Silica-Supported Aluminum Chloride-Assisted Solution Phase Synthesis of Pyridazinone-Based Antiplatelet Agents

  摘要：

  A solution phase protocol that enabled the synthesis of three diverse libraries of pyridazin-3-ones incorporating alpha,beta-unsaturated moieties at position S of the heterocyclic core has been developed using silica-supported aluminum trichloride as a heterogeneous and reusable catalyst. This robust procedure has facilitated the hit to lead process for these series of compounds and allowed the identification of new potent derivatives that elicit antiplatelet activity in the low micromolar range.

  DOI：

  10.1021/co100017h

文献信息

• PYRIDAZINONE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：US20160075710A1

  公开（公告）日：2016-03-17

  Compounds of formula (I) described herein inhibit phosphoinositide 3-kinases (PI3K) and useful for the treatment of disorders associated with PI3K enzymes.

  本文描述的化合物(I)抑制磷脂酰肌醇3-激酶（PI3K），并可用于治疗与PI3K酶相关的疾病。
• PYRIDAZINONE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS
  申请人：Chiesi Farmaceutici S.p.A.

  公开号：EP3191491B1

  公开（公告）日：2019-09-04
• US9745308B2
  申请人：——

  公开号：US9745308B2

  公开（公告）日：2017-08-29
• [EN] PYRIDAZINONE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDAZINONE À TITRE D'INHIBITEURS DE PHOSPHOINOSITIDE 3-KINASES
  申请人：CHIESI FARMA SPA

  公开号：WO2016038140A1

  公开（公告）日：2016-03-17

  The invention relates to compounds of formula (I) inhibiting phosphoinositide 3-kinases (PI3K), to pharmaceutical compositions comprising them, and to therapeutic uses thereof in the treatment of disorders associated with PI3K enzymes such as respiratory diseases, allergic diseases, autoimmune diseases or inflammatory disorders.